No 10Y consistency score for revenue — its stored periods are half-year spaced, so quarter-over-same-quarter consistency is not computed.
Valuation vs own 10Y history: P/S 2.1x · 10Y median 2.2x · 50th percentile · as of Oct 6, 2026
Annual revenue · last 10 fiscal years + TTM
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:35:23.183Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for 20/20 Biolabs Inc. (AIDX) stock was $0.35 as of Oct 6, 2026, 10:34 AM EDT, down 0.71% from the previous close.
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services.
Medical - Care Facilities · Gaithersburg, MD
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.26
vs Estimate
$-0.12
Revenue
$730571.00
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1AIDX | $4.29M | $0.35 | -0.71% | N/A | N/A | N/A | N/A |
| 2GRI | $4.18M | $1.91 | +0.00% | -96.44% | -95.39% | N/A | vs AIDX |
| 3CLGN | $4.43M | $3.42 | +0.29% | -85.66% | -53.69% | N/A | vs AIDX |
| 4DRMA | $4.50M | $1.12 | +0.90% | -77.00% | -83.90% | N/A | vs AIDX |
| 5APVO | $4.02M | $1.84 | +2.08% | -92.21% | -95.30% | -80.35% | vs AIDX |
| 6ERNA | $4.00M | $2.45 | -9.26% | -90.95% | -86.83% | -65.14% | vs AIDX |
forward FY estimate
N/A
vs Estimate
$636000.00
Consensus Rating
Based on 1 analyst
Average Price Target
$5.00
+1329.0% upside
Low
$5.00
Current
$0.35
High
$5.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Quarter ending Dec 2026 | $-0.07 | $-0.07 | $-0.07 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.42 | $-0.42 | $-0.42 | 1 |
| FY 2027 | $-0.38 | $-0.38 | $-0.38 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $891000.00 | $891000.00 | $891000.00 | 1 |
| Quarter ending Dec 2026 | $1.07M | $1.07M | $1.07M | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $2.95M | $2.95M | $2.95M | 1 |
| FY 2027 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| $5.77M |
| $5.77M |
| $5.77M |
| 1 |
